The Bharat Biotech’s Covid-19 vaccine ‘Covaxin’ works effectively on the Delta Plus variant of Coronavirus, according to a study published in the Indian Council of Medical and Research (ICMR) Biorxivby.
The study found that two doses of Covaxin given for the people infected with the Delta Plus variant increased IgM antibodies in the body and helped victims recover. It is 65.2% efficient on the Delta variant on the third phase 3 clinical trials.
Bharat Biotech has shown an overall vaccine efficacy of 77.8% based on the results from the Phase 3 trials. The Phase 3 trials also showed that the Hyderabad-based company’s vaccine efficacy against asymptomatic Coronavirus was 63.6%, while it was 65.2% against the Delta variant (B.1.617.2).
The number of Covid-19 vaccine doses administered in the country has crossed the 46 crore milestone. A total of 46,15,18,479 doses of vaccine have been administered through 54,94,423 camps, the Union Health Ministry said on Saturday.